Literature DB >> 1424412

Effects of temazepam on saccadic eye movements: concentration-effect relationships in individual volunteers.

A L van Steveninck1, S Verver, H C Schoemaker, M S Pieters, R Kroon, D D Breimer, A F Cohen.   

Abstract

Saccadic eye movements were analyzed after single oral doses of 20 mg temazepam and placebo in a randomized, double-blind crossover study in eight healthy volunteers. For an optimal evaluation of concentration-effect relationships, 18 blood samples and 43 effect measures were obtained over 33 1/2 hours. After placebo, saccadic peak velocity decreased within the first hour, with average values remaining 6.2% to 12.1% below baseline up to 15 hours after intake. After temazepam, significant changes in peak velocity occurred for 5 hours, with maximum decreases averaging 29.2% (95% confidence interval, 10.0 to 37.2). The apparent duration of effects ranged from 3 to 9 hours in individual subjects. Linear concentration-effect relationships were demonstrated for peak velocity, with individual slopes ranging from -0.11 to -0.46 deg/sec.(ng/ml)-1 (average r = -0.82, all p < 0.01). Differences in protein binding of temazepam did not account for the approximate fourfold variability in individual sensitivities to temazepam. By increasing the frequency of measurements, the accuracy of pharmacodynamic evaluations was clearly enhanced in this study.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1424412     DOI: 10.1038/clpt.1992.162

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  13 in total

Review 1.  Biomarkers for the effects of antipsychotic drugs in healthy volunteers.

Authors:  S J de Visser; J van der Post; M S Pieters; A F Cohen; J M van Gerven
Journal:  Br J Clin Pharmacol       Date:  2001-02       Impact factor: 4.335

2.  Estimating potency for the Emax-model without attaining maximal effects.

Authors:  R C Schoemaker; J M van Gerven; A F Cohen
Journal:  J Pharmacokinet Biopharm       Date:  1998-10

Review 3.  Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development. The "wooden shoe' paradigm.

Authors:  D D Breimer; M Danhof
Journal:  Clin Pharmacokinet       Date:  1997-04       Impact factor: 6.447

4.  Pharmacology in translation: the preclinical and early clinical profile of the novel α2/3 functionally selective GABAA receptor positive allosteric modulator PF-06372865.

Authors:  Sarah A Nickolls; Rachel Gurrell; Guido van Amerongen; Juha Kammonen; Lishuang Cao; Adam R Brown; Clara Stead; Andy Mead; Christine Watson; Cathleen Hsu; Robert M Owen; Andy Pike; Rebecca L Fish; Laigao Chen; Ruolun Qiu; Evan D Morris; Gang Feng; Mark Whitlock; Donal Gorman; Joop van Gerven; David S Reynolds; Pinky Dua; Richard P Butt
Journal:  Br J Pharmacol       Date:  2018-01-18       Impact factor: 8.739

5.  Pharmacodynamic interactions of diazepam and intravenous alcohol at pseudo steady state.

Authors:  A L van Steveninck; R Gieschke; H C Schoemaker; M S Pieters; J M Kroon; D D Breimer; A F Cohen
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 6.  Biomarkers for the effects of benzodiazepines in healthy volunteers.

Authors:  S J de Visser; J P van der Post; P P de Waal; F Cornet; A F Cohen; J M A van Gerven
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335

7.  The central nervous system effects of the partial GABA-Aα2,3 -selective receptor modulator AZD7325 in comparison with lorazepam in healthy males.

Authors:  Xia Chen; Gabriël Jacobs; Marieke de Kam; Judith Jaeger; Jaakko Lappalainen; Paul Maruff; Mark A Smith; Alan J Cross; Adam Cohen; Joop van Gerven
Journal:  Br J Clin Pharmacol       Date:  2014-12       Impact factor: 4.335

8.  A comparison of the concentration-effect relationships of midazolam for EEG-derived parameters and saccadic peak velocity.

Authors:  A L Van Steveninck; J W Mandema; B Tuk; J G Van Dijk; H C Schoemaker; M Danhof; A F Cohen
Journal:  Br J Clin Pharmacol       Date:  1993-08       Impact factor: 4.335

Review 9.  Pharmacokinetic-pharmacodynamic relationships for benzodiazepines.

Authors:  B E Laurijssens; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  1996-01       Impact factor: 6.447

Review 10.  Pharmacological treatment effects on eye movement control.

Authors:  James L Reilly; Rebekka Lencer; Jeffrey R Bishop; Sarah Keedy; John A Sweeney
Journal:  Brain Cogn       Date:  2008-12       Impact factor: 2.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.